Breaking News Instant updates and real-time market news.

ADMA

ADMA Biologics

$4.82

-0.13 (-2.63%)

07:10
04/17/19
04/17
07:10
04/17/19
07:10

ADMA Biologics granted U.S. patent for treatment, prevention of S. pneumonia

ADMA Biologics announced that the United States Patent and Trademark Office issued to the company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection. The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti-pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti-pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti-pneumococcal immune globulin. This patent will enable ADMA to protect its proprietary rights and at the same time attract collaborators interested in the development, marketing and commercialization of a therapeutic for the treatment and prevention of infection in immune compromised, immunodeficient and elderly patients who are poorly responsive to available S. pneumonia vaccines. The term of the patent extends to March 2037.

ADMA ADMA Biologics
$4.82

-0.13 (-2.63%)

10/30/18
HCWC
10/30/18
INITIATION
Target $17
HCWC
Buy
ADMA Biologics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started ADMA Biologics with a Buy rating and $17 price target. ADMA has transformed itself into a fully integrated company with multiple products and a manufacturing operation, all of which should support its original mission, to commercialize RI-002, Kolbert tells investors in a research note.
02/07/19
HCWC
02/07/19
INITIATION
Target $10
HCWC
Buy
ADMA Biologics assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju assumed coverage of ADMA Biologics with a Buy rating and $10 price target. The analyst believes the current valuation constitutes an attractive entry point. If the FDA accepts its filing, Bivigam could be authorized to re-enter the market within the next few months, says the analyst. ADMA could easily return Bivigam to the sales it had previously reached, exceeding $50M annually, he estimates.
04/04/19
WBBS
04/04/19
UPGRADE
Target $11.5
WBBS
Buy
ADMA Biologics upgraded to Buy from Speculative Buy at WBB Securities
WBB Securities analyst Stephen Brozak upgraded ADMA Biologics to Buy from Speculative Buy after the company received FDA approval for Asceniv, which he views as an important milestone. Brozak raised his price target on ADMA shares to $11.50 from $9.00.
04/15/19
HCWC
04/15/19
NO CHANGE
Target $13
HCWC
Buy
ADMA Biologics price target raised to $13 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ADMA Biologics to $13 from $10 following FDA approval of RI-002. Further, the analyst continues to expect near-term feedback from the FDA on ADMA's response to the Complete Response Letter for Bivigam that the FDA issued in late December 2018. The approval of RI-002 should have favorable implications for the approval of the Bivigam, says the analyst. He reiterates a Buy rating on ADMA Biologics.

TODAY'S FREE FLY STORIES

SCHW

Charles Schwab

$45.57

-0.53 (-1.15%)

17:04
04/19/19
04/19
17:04
04/19/19
17:04
Conference/Events
Charles Schwab to hold a webcast »

Management holds a 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 15

    May

12:45
04/19/19
04/19
12:45
04/19/19
12:45
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

MMNFF

MedMen

$0.00

(0.00%)

11:13
04/19/19
04/19
11:13
04/19/19
11:13
Hot Stocks
MedMen announces resignations of COO and General Counsel »

MedMen Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKC

Turkcell

$5.49

-0.175 (-3.09%)

11:08
04/19/19
04/19
11:08
04/19/19
11:08
Hot Stocks
Turkcell sees conclusion of $4.2B lawsuit against MTN this year »

The following statement…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCCY

1st Constitution Bancorp

$18.07

-0.14 (-0.77%)

11:05
04/19/19
04/19
11:05
04/19/19
11:05
Earnings
1st Constitution Bancorp reports Q1 EPS 39c, two estimates 36c »

Robert Mangano, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QUMU

Qumu

$2.83

-0.035 (-1.22%)

11:03
04/19/19
04/19
11:03
04/19/19
11:03
Hot Stocks
Qumu announces death of director Thomas Madison »

Qumu Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 09

    May

FAT

Fat Brands

$5.15

0.065 (1.28%)

10:54
04/19/19
04/19
10:54
04/19/19
10:54
Hot Stocks
Fat Brands announces development of Fatburger concept in Albuquerque »

FAT Brands announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTG

Heritage Insurance

$14.32

0.25 (1.78%)

10:52
04/19/19
04/19
10:52
04/19/19
10:52
Hot Stocks
Heritage Insurance announces preliminary Q1 catastrophe losses of $15.4M »

Heritage Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

COTY

Coty

$11.27

0.02 (0.18%)

10:48
04/19/19
04/19
10:48
04/19/19
10:48
Hot Stocks
Coty notes extension of tender offer by affiliate of JAB Holding Company »

Coty notes the extension…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTES

NetEase

$265.88

-2.34 (-0.87%)

10:45
04/19/19
04/19
10:45
04/19/19
10:45
Hot Stocks
NetEase announces music license agreement with Nippon Columbia »

NetEase Cloud Music…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
04/19/19
04/19
09:10
04/19/19
09:10
General news
Today's U.S. housing report revealed March declines »

Today's U.S. housing…

08:45
04/19/19
04/19
08:45
04/19/19
08:45
General news
U.S. housing starts fell 0.3% to 1.139 M in March »

U.S. housing starts fell…

08:15
04/19/19
04/19
08:15
04/19/19
08:15
General news
Housing Starts to be reported at 08:30 »

March Housing Starts will…

08:15
04/19/19
04/19
08:15
04/19/19
08:15
General news
Housing Starts Permits to be reported at 08:30 »

March Housing Starts…

08:05
04/19/19
04/19
08:05
04/19/19
08:05
General news
U.S. housing starts preview: »

U.S. housing starts…

NDEKY

Nitto Denko

$0.00

(0.00%)

06:53
04/19/19
04/19
06:53
04/19/19
06:53
Downgrade
Nitto Denko rating change at Goldman Sachs »

Nitto Denko downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURO

Curo Group

$10.96

0.16 (1.48%)

04:55
04/19/19
04/19
04:55
04/19/19
04:55
Conference/Events
Curo Group management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 16

    May

  • 05

    Jun

  • 13

    Nov

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Breaking General news story  »

Week of 4/19 Baker-Hughes…

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Housing Starts Permits to be reported at 08:30 »

March Housing Starts…

AON

Aon plc

$175.38

-0.14 (-0.08%)

, MMC

Marsh & McLennan

$93.76

-0.62 (-0.66%)

04:55
04/19/19
04/19
04:55
04/19/19
04:55
Conference/Events
Willis Towers Watson »

Analyst Klauber holds a…

AON

Aon plc

$175.38

-0.14 (-0.08%)

MMC

Marsh & McLennan

$93.76

-0.62 (-0.66%)

WLTW

Willis Towers Watson

$177.37

0.45 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

  • 26

    Apr

  • 01

    May

  • 07

    May

  • 16

    May

  • 20

    May

  • 11

    Jun

04:55
04/19/19
04/19
04:55
04/19/19
04:55
General news
Housing Starts to be reported at 08:30 »

March Housing Starts will…

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

21:07
04/18/19
04/18
21:07
04/18/19
21:07
Recommendations
Intuitive Surgical analyst commentary at Piper Jaffray »

Intuitive Surgical price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 25

    Apr

  • 03

    May

UBER

Uber

$0.00

(0.00%)

, TM

Toyota

$125.10

0.93 (0.75%)

20:35
04/18/19
04/18
20:35
04/18/19
20:35
Hot Stocks
Uber confirms investment from Toyota, DENSO and SoftBank Vision Fund »

Toyota Motor (TM), Denso…

UBER

Uber

$0.00

(0.00%)

TM

Toyota

$125.10

0.93 (0.75%)

DNZOY

Denso

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

FIX

Comfort Systems USA

$57.58

0.06 (0.10%)

20:08
04/18/19
04/18
20:08
04/18/19
20:08
Hot Stocks
Comfort Systems USA discloses ransomware attack virus »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 12

    Jun

  • 13

    Jun

NSANY

Nissan

$0.00

(0.00%)

, RNSDF

Renault

$0.00

(0.00%)

19:29
04/18/19
04/18
19:29
04/18/19
19:29
Periodicals
Nissan to cut global output by 15% in FY19/20, Nikkei reports »

Nissan Motor (NSANY) will…

NSANY

Nissan

$0.00

(0.00%)

RNSDF

Renault

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.